These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 18594792)

  • 21. Anti-atherogenic effects of the combination therapy with olmesartan and azelnidipine in diabetic apolipoprotein E-deficient mice.
    Noda K; Hosoya M; Nakajima S; Ohashi J; Fukumoto Y; Shimokawa H
    Tohoku J Exp Med; 2012 Dec; 228(4):305-15. PubMed ID: 23124103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rosuvastatin prevents angiotensin II-induced vascular changes by inhibition of NAD(P)H oxidase and COX-1.
    Colucci R; Fornai M; Duranti E; Antonioli L; Rugani I; Aydinoglu F; Ippolito C; Segnani C; Bernardini N; Taddei S; Blandizzi C; Virdis A
    Br J Pharmacol; 2013 Jun; 169(3):554-66. PubMed ID: 22817606
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rosuvastatin improves endothelial function in db/db mice: role of angiotensin II type 1 receptors and oxidative stress.
    Tian XY; Wong WT; Xu A; Chen ZY; Lu Y; Liu LM; Lee VW; Lau CW; Yao X; Huang Y
    Br J Pharmacol; 2011 Sep; 164(2b):598-606. PubMed ID: 21486274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Atorvastatin improves plaque stability in diabetic atherosclerosis through the RAGE pathway.
    Zhou F; Tan Y; Chen XH; Wu FL; Yang DJ; Zhang XW; Wu XM; Deng YQ
    Eur Rev Med Pharmacol Sci; 2018 Feb; 22(4):1142-1149. PubMed ID: 29509268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy.
    Abe M; Maruyama N; Okada K; Matsumoto S; Matsumoto K; Soma M
    J Atheroscler Thromb; 2011; 18(11):1018-28. PubMed ID: 21921413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis.
    Moura LM; Ramos SF; Zamorano JL; Barros IM; Azevedo LF; Rocha-Gonçalves F; Rajamannan NM
    J Am Coll Cardiol; 2007 Feb; 49(5):554-61. PubMed ID: 17276178
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes.
    Soro-Paavonen A; Watson AM; Li J; Paavonen K; Koitka A; Calkin AC; Barit D; Coughlan MT; Drew BG; Lancaster GI; Thomas M; Forbes JM; Nawroth PP; Bierhaus A; Cooper ME; Jandeleit-Dahm KA
    Diabetes; 2008 Sep; 57(9):2461-9. PubMed ID: 18511846
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiac hypertrophy during hypercholesterolemia and its amelioration with rosuvastatin and amlodipine.
    Kang BY; Wang W; Palade P; Sharma SG; Mehta JL
    J Cardiovasc Pharmacol; 2009 Oct; 54(4):327-34. PubMed ID: 19687748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL- and LDL-ApoB kinetics in type 2 diabetes.
    Vergès B; Florentin E; Baillot-Rudoni S; Monier S; Petit JM; Rageot D; Gambert P; Duvillard L
    Diabetologia; 2008 Aug; 51(8):1382-90. PubMed ID: 18535816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of combined treatment with an angiotensin II receptor antagonist and an HMG-CoA reductase inhibitor on atherosclerosis in genetically hyperlipidemic rabbits.
    Kato M; Sada T; Mizuno M; Kitayama K; Inaba T; Koike H
    J Cardiovasc Pharmacol; 2005 Oct; 46(4):556-62. PubMed ID: 16160612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction.
    Kristensen SL; Køber L; Jhund PS; Solomon SD; Kjekshus J; McKelvie RS; Zile MR; Granger CB; Wikstrand J; Komajda M; Carson PE; Pfeffer MA; Swedberg K; Wedel H; Yusuf S; McMurray JJ
    Circulation; 2015 Jan; 131(1):43-53. PubMed ID: 25406306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia].
    Gómez-García A; Martínez Torres G; Ortega-Pierres LE; Rodríguez-Ayala E; Alvarez-Aguilar C
    Rev Esp Cardiol; 2007 Dec; 60(12):1242-9. PubMed ID: 18082089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.
    Rizos CV; Milionis HJ; Kostapanos MS; Florentin M; Kostara CE; Elisaf MS; Liberopoulos EN
    Clin Ther; 2010 Mar; 32(3):492-505. PubMed ID: 20399986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Impact of rosuvastatin on atherosclerosis lesions in apolipoprotein E knockout mice].
    Luo RN; Tao LJ; Zhou J; Wang R; Lu MM; Fu X
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Aug; 39(8):743-8. PubMed ID: 22169423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of accelerated atherosclerosis by AT1 receptor blockade in experimental renal failure.
    Bernardi S; Candido R; Toffoli B; Carretta R; Fabris B
    Nephrol Dial Transplant; 2011 Mar; 26(3):832-8. PubMed ID: 20810455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rosuvastatin in elderly patients.
    Davidson MH
    Drugs Aging; 2007; 24(11):933-44. PubMed ID: 17953460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rosuvastatin ameliorates high-fat and high-cholesterol diet-induced nonalcoholic steatohepatitis in rats.
    Okada Y; Yamaguchi K; Nakajima T; Nishikawa T; Jo M; Mitsumoto Y; Kimura H; Nishimura T; Tochiki N; Yasui K; Mitsuyoshi H; Minami M; Kagawa K; Okanoue T; Itoh Y
    Liver Int; 2013 Feb; 33(2):301-11. PubMed ID: 23295058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of cardiovascular dysfunction associated with the metabolic syndrome and type 2 diabetes.
    Oltman CL; Kleinschmidt TL; Davidson EP; Coppey LJ; Lund DD; Yorek MA
    Vascul Pharmacol; 2008 Jan; 48(1):47-53. PubMed ID: 18164667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of rosuvastatin and colestimide on metabolic parameters and urinary monocyte chemoattractant protein-1 in type 2 diabetic patients with hyperlipidemia.
    Takebayashi K; Suetsugu M; Matsumoto S; Aso Y; Inukai T
    South Med J; 2009 Apr; 102(4):361-8. PubMed ID: 19279518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rosuvastatin stabilizes atherosclerotic plaques by reducing CD40L overexpression-induced downregulation of P4Hα1 in ApoE
    Wang XL; Sun W; Zhou YL; Li L
    Int J Biochem Cell Biol; 2018 Dec; 105():70-77. PubMed ID: 30336263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.